Effect of Brewers yeast on blood glucose level and blood pressure in patients with type 2 diabetes mellitus

Not Applicable

Conditions: on-insulin-dependent diabetes mellitus.
Non-insulin-dependent diabetes mellitus

Registration Number: IRCT138807062513N1

Lead Sponsor: Tehran University of Medical Science

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 80

Inclusion Criteria

History of at least 2 years clinically diagnosed type 2 diabetes mellitus; taking oral hypoglycemic drugs ; Fasting blood glucose at least more than 125 mg/dl; Not consuming brewers yeast during the last 3 months; Aged 35-55 years; Signing the informed consent form (attached). Exclusion criteria: History of hepatitis, cardiovascular, renal and Parkinson's diseases, gout and depression disorder, A record of angina pectoris, myocardial and cerebral infarction during the last year; History of infectious disease or common cold during the last 4 weeks; Regular consumption of anti-inflammatory drugs (steroid or non-steroid) or monoamine oxidase inhibitors; Insulin therapy; Consumption of brewers yeast or placebo less than 12 weeks; Any side effects due to supplementation; Change in diet or hypoglycemic drugs; Unwilling to continue taking supplementation.

Exclusion Criteria

Not provided

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fasting Blood Sugar. Timepoint: Baseline, After 12 weeks. Method of measurement: Blood Analysis: GOD / PAP method.;Glycosylated hemoglobin. Timepoint: Baseline, After 12 weeks. Method of measurement: Blood Analysis: boronate affinity assay.;HOMA-IR (homeostatic model assessment of insulin resistance). Timepoint: Baseline, After 12 weeks. Method of measurement: computed as fasting plasma glucose (mmol/L) × fasting serum insulin (mU/L) / 22.5.;QUICKI ( quantitative insulin sensitivity check index ). Timepoint: Baseline, After 12 weeks. Method of measurement: calculated as 1/ [log insulin (µIU/ml) + log glucose (mg/dl) ].;Systolic Blood pressure. Timepoint: Baseline, After 12 weeks. Method of measurement: Mercury sphygmomanometer.;Diastolic blood pressure. Timepoint: Baseline, After 12 weeks. Method of measurement: Mercury sphygmomanometer.

Secondary Outcome Measures

Name	Time	Method
Triglyceride. Timepoint: Baseline, After 12 weeks. Method of measurement: Blood Analysis: colorimetric method.;Total cholesterol. Timepoint: Baseline, After 12 weeks. Method of measurement: Blood Analysis: colorimetric method.;High Density Lipoprotein (HDL-c). Timepoint: Baseline, After 12 weeks. Method of measurement: Blood Analysis: Enzymatic method.;Low Density Lipoprotein (LDL-c). Timepoint: Baseline, After 12 weeks. Method of measurement: Blood Analysis: Enzymatic method.;Height. Timepoint: Baseline. Method of measurement: stadiometer (seca 206).;Weight. Timepoint: Baseline, After 12 weeks. Method of measurement: Digital scale (seca762).;Body Mass Index (BMI). Timepoint: Baseline, After 12 weeks. Method of measurement: Calculate.;Three days food intakes. Timepoint: Baseline, After 12 weeks. Method of measurement: 24-hour food recall.